Continuous glucose monitors (CGMs) are game changers for many people with type 1 diabetes (T1D). The ability to view trends in blood sugar, treat blood sugar highs and lows before they get out of control and to be alarmed when treatment is needed, such as in the middle of the night or when someone has hypoglycemic unawareness, are all incredibly helpful to the patient community. According to the T1D Exchange Clinic Registry, CGM users have lower HbA1cs, on average, than non-CGM users.
But there is still work to be done in making these devices more accessible, as well as making the patients and providers who use them more successful in achieving their diabetes management goals. That’s why I’m joining Chief Medical Officer Henry Anhalt, DO, to represent the Glu community at the American Association of Clinical Endocrinologists’ (AACE) and American College of Endocrinology’s (ACE) Consensus Conference on Continuous Glucose Monitoring in Washington, DC, this weekend.
In order to write their standards of care for CGM devices and data, AACE has invited representatives from four key “Pillars” of support and information. The pillars of support are:
- Medical/Scientific/Professional & Educational Societies,
- Patient/Lay Organizations,
- Government/Regulatory/Payors/Employers, and
- Industry Organizations
Dr. Anhalt and I will represent Glu on the Patient/Lay Organization Pillar to provide feedback from you, our Glu community, on this very important topic. Dr. Anhalt has been asked to serve as a Co-moderator of the panel, and I will be a participant. We look forward to providing input on CGM issues and challenges through Glu data, recently collected via our Questions of the Day and a T1D Exchange study on severe hypoglycemia.
“This is an excellent opportunity to provide real-world patient feedback to impact outcomes and standards of clinical care,” said Dr. Anhalt.
The AACE/ACE Consensus Conference will be collecting feedback on 4 specific questions:
- How would patients, practitioners and payers benefit from expanded use of personal and professional CGM?
- What CGM data is relevant and how should it be reported?
- How should the data and reporting be interpreted?
- What clinical data is currently available to support expanded CGM coverage by payers as pertains to Questions 1-and 3? What additional data is needed?
After each member of the patient pillar has presented their answers and supporting data, the AACE/ACE Writing Committee will convene to combine this input into their Standards of Care document. We will certainly share whatever outcomes and updates we can throughout the weekend and in subsequent weeks.
To all who have answered our Questions of the Day on CGM use in the past, thank you. We are proud to see our data included in the meeting materials and look forward to sharing your feedback to improve care and access to this invaluable device.
—Amy Bevan (GluMom)